16 Steps

Sign in to view your progression
Programme overview
Learning objectives
Target audience
Abbreviations

An Introduction to Clinical Lipidology, October 2019

These recordings were made at an EAS Course "An Introduction to Clinical Lipidology" organised on behalf of Daiichi Sankyo as part of a training programme for the company's personnel, October 2019.

Presentations include:

  • Lipoprotein metabolism & the casual role of LDL in Atherosclerosis, by Prof Jan Borén
  • Cardiovascular disease risk classification by Prof Lale Tokgozoglu
  • The new guidelines for dyslipidaemia by Prof Heinz Drexel
  • Looking deeper into the Guidelines:
    why do we need goals?
    Acute Coronary syndrome (ACS) and very high-risk patients
    Diabetic patients
    FH patients
  • Mendelian randomization by Prof Brian Ference
  • Currently available therapies - a closer look:
    Ezetimibe
    PCSK9 inhibition
    Omega 3 and fibrates
    Statins
  • Bempedoic acid
    Mechanism of action
    The clinical experience
    Ongoing studies

These recordings were made at an EAS Course "An Introduction to Clinical Lipidology" organised on behalf of Daiichi Sankyo as part of a training programme for the company's personnel, October 2019.

Participants in this Programme will improve their understanding of the role of lipids in health and disease on several different levels. These different levels include:

  • basic understanding of lipids chemistry and lipoprotein metabolism
  • the role of lipids as risk factors
  • the mechanisms of lipids in cardiovascular disease
  • understanding of lipid disorders and the role of genetics and environmental factors
  • pharmacological interventions against lipid disorders
  • the clinical development of lipids
  • lipid-lowering treatment in cardiovascular prevention and the development of new therapeutic targets

Understanding the role of lipids in health and disease is important for a broad spectrum of different professionals working in health care and in society at large. This educational programme is suited to scientists working in cardiovascular epidemiology and in basic cardiovascular research, and persons employed in the pharma industry.

ACLF - Acute on Chronic Liver Failure
Acrp30 - Adiponectin
ACS - Acute Coronary Syndrome
ADA - American Diabetes Association
ADMA - asymmetrical dimethylarginine
AGE - Advanced glycation end product
AGEs - Advanced Glycation Endproducts
AGI - Alpha Glucosidase Inhibitors
alpha 2-beta AR - alpha 2-beta adrenergic receptors
ALT - Alanine Aminotransferase
AMPK - Adenosine Monophosphate activated Protein Kinase
apM1 - Adiponectin
ARB - Angiotensin Receptor Blocker
ATP III - Adult Treatment Panel
BAD - Brachial Artery Distensibility
BCDI - Beta-Cell Demand Index
BCS - Budd-Chiari Syndrome
BDA - British Diabetic Association
BIP - Bezafibrate Infarction Prevention
BMI - Body Mass Index
CAD - Coronary Artery Disease
cccDNA - closed circular DNA
CCK - Cholecystokinin
CHD - Coronary Heart Disease
CHF - Congestive Heart Failure
CLA - Conjugated Linoleic Acid
CNTF - Ciliary Neurotrophic Factor
CRP - C reactive protein
CVD - cardiovascular disease
DASIMAR - the summed product of ADMA and SDMA
DASIMAR - score
DASIMAR - score of the sum of DAS and IMAR
DKA - Diabetic Ketoacidosis
DM - diabetes mellitus
DPP - Diabetes Prevention Program
EBL - Endoscopic band ligation
EGIR - European Group for the study of Insulin Resistance
EWET - Enlarged Waist with Elevated Triacylglycerols
FA - Fatty Acid
FAAH - Fatty Acid Amide Hydrolase
FBG - fasting blood glucose
FDA - Food and Drug Agency
FFAs - Free Fatty Acids
FIAF - Fasting Induced Adipose Factor
FMD - Flow-Mediated Dilation
FPG - fasting plasma glucose
FPI - Fasting Plasma Insulin
GI - Glycemic Index
GIK Therapy - Glucose-Insulin-Potassium Therapy
HbA1c - Glycosylated Hemoglobin A1C
HDL - high-density lipoprotein
HMO - Health Maintenance Organization
HOMA - Homeostasis Model Assessment
HPA - Hypothalamic-Pituitary-Adrenal
HRS - hepatorenal syndrome
HVPG - hepatic venous pressure gradient
IAPP - islet amyloid polypeptide
ICCU - Intensive Cardiac Care Unit
IDF - International Diabetes Federation
IFH - isolated fasting hyperglycemia
IGR - impaired glucose regulation
IGT - impaired glucose tolerance
IL-6 - Interleukin-6
IMCL - Intramyocellular Lipids
IMT - Intima-media Thickness
IPH - isolated postchallenge hyperglycemia
IPMN - intraductal papillary mucinous neoplasm
LDL - low-density lipoprotein
LDLT - Living donor liver transplantation
MGSD - Mediterranean Group for the Study of Diabetes
MI - Myocardial Infarction
NCEP - National Cholesterol Education Program
NGR - Normal glucose regulation
NGT - Normal glucose tolerance
NHS - Nurses' Health Study
OGTT - Oral Glucose Tolerance Test
PAI-1 - Plasminogen Activator Inhibitor Type 1
PGC-1 alpha - peroxisome proliferator-activated receptor gamma coactivator-1 alpha
PMN - Polymorphonuclear Neutrophil
PPAR gamma - peroxisome proliferator activated receptors
PPG - Postprandial Glucose
PSA - Prostate specific antigen
PWV - Pulse Wave Velocity
PWV - Pulse Wave Velocity
QOL - Quality of life
RAGE - Receptor for AGE
RAI - Radioactive iodine
RAI Scanning - Radioactive Iodine Scanning
RECIST - Response Evaluation Criteria In Solid Tumors
RNAi - RNA interference
RR - Relative risk
RXR - retinoid X receptors
SAA - Serum Amyloid A
SADLE - San Antonio Diabetes Likelihood Equation
SCL - Sclerotherapy
SDMA - symmetric dimethylarginine
SIRS - Systemic inflammatory response syndrome
SOFA - Sepsis-related Organ Failure Assessment
SU - sulfonylurea
T2D - type 2 diabetes
T4/T3 - Thyroxine
TERalb - Transcapillary Escape Rate of Albumin
TG - triglyceride
TIPS - Transjugular intrahepatic portosystemic shunt
TNF-alpha - Tumor Necrosis Factor alpha
TZD - Thiazolidinedione
UCP2 - Uncoupling Protein 2
VIP - Vasterbotten Intervention Program
VSMC - Vascular Smooth Muscle Cells
WC - Waist Circumference
WHO - World Health Organization

Course presentations: An Introduction to Clinical Lipidology, October 2019
Plenary session: Lipoprotein metabolism & the casual role of LDL in atherosclerosis
Plenary session: CV disease risk classification
Plenary session: The new guidelines for dyslipidaemia
Group session: In depth knowledge about Guidelines: The goals - why?
Group session: In depth knowledge about Guidelines: Acute coronary syndrome (ACS) & very high-risk patients
Group session: In depth knowledge about Guidelines: Diabetic patients
Group session: In depth knowledge about Guidelines: FH patients
Plenary session: Mendelian randomization
Group session: In-depth knowledge about currently available therapies: Ezetimibe
Group session: In-depth knowledge about currently available therapies: PCSK9 inhibition
Group session: In-depth knowledge about currently available therapies: Omega3 & fibrates
Group session: In-depth knowledge about currently available therapies: Statins
Plenary session: Bempedoic acid: Mechanism of action
Plenary session: Bempedoic acid: The clinical experience
Plenary session: Bempedoic acid: Ongoing studies

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies